



中國臍帶血庫企業集團
China Cord Blood Corporation

China Cord Blood Corporation Announces Results of 2012 Annual General Meeting

HONG KONG, China, December 20, 2012 - China Cord Blood Corporation (NYSE: CO) (“CCBC” or the “Company”), the first and largest cord blood banking operator in China, today announced the results of its 2012 Annual General Meeting, which was held on December 19, 2012, in Hong Kong.

At the Annual General Meeting, shareholders

- Ratified the appointment of KPMG as the independent auditor of the Company for the financial year ending March 31, 2013, and authorized any duly formed committee of the directors to fix the remuneration of the auditors; and
- Elected Mr. Yuen Kam, Mr. Julian J. Wolhardt and Ms. Jennifer J. Weng to serve on the Board of Directors until the 2015 Annual General Meeting of the Company or until their respective successors are duly appointed and qualified, and Mr. Yuen Kam will be the chairman of the board of directors; and
- Passed a special resolution to amend the articles of association of the Company to change the threshold required to approve future special resolutions from 75% of the votes cast to 66 2/3%, and authorized the directors to make all necessary filings in respect of the amendments to the article of association.

About China Cord Blood Corporation

China Cord Blood Corporation is the first and largest cord blood banking operator in China in terms of geographical coverage and the only cord blood banking operator with multiple licenses. Under current PRC government regulations, only one licensed cord blood banking operator is permitted to operate in each licensed region and only seven licenses have been authorized as of today. China Cord Blood Corporation provides cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services. For more information, please visit our website at <http://www.chinacordbloodcorp.com>.

Safe Harbor Statement

This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events, performance and results of operations, and underlying assumptions and other statements that are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, and other risks contained in statements filed from time to time with the U.S. Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the Company, are expressly qualified by the cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the Company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.

For more information, please contact:

China Cord Blood Corporation
Investor Relations Department
Tel: (+852) 3605-8180
Email: ir@chinacordbloodcorp.com



中國臍帶血庫企業集團

China Cord Blood Corporation

ICR, Inc.

Mr. Rob Koeppe

Tel: (+86) 10-6583-7516 (China) or (646) 405-5185 (U.S.)

Email: robert.koeppe@icrinc.com